U.S. Insights: Top 20 Small-Molecule Brand Drugs Facing Generic Competition by Year-End 2026

IPD Analytics has released a new Data STACK Trend Report, “U.S. Insights: Top 20 Small-Molecule Brand Drugs Facing Generic Competition by Year-End 2026.” This report examines the top 20 small-molecule brand drugs, including 13 blockbuster products, that may face first-time generic competition by the end of 2026. It also provides a detailed assessment of market, regulatory, and technical factors that will shape this significant wave of potential loss of exclusivity (LOE). Our analysis offers insights into expected timelines for generic entry, anticipated competitive impacts, and the implications for manufacturers, payers, and patients as the market prepares for one of the most consequential LOE cycles in recent years.

Content on this site is proprietary to IPD Analytics. By receiving this sample you are agreeing to refrain from any unauthorized use, including uploading or inputting into AI tools or large language models for any purpose, is strictly prohibited.